EuroPCR 2026 Dominates TCTMD’s Top Cardiovascular Stories of May
EuroPCR 2026 Dominates TCTMD’s Top Cardiovascular Stories of May
Source: TCTMD Editor’s Corner | June 1, 2026
1. EuroPCR 2026 – Immediate Complete PCI May Harm STEMI Patients With Multivessel CAD
* Findings support a staged PCI strategy rather than immediate complete revascularization in STEMI patients with multivessel coronary disease.
2. EuroPCR 2026 – evolocumab Reduces Cardiovascular Events After PCI
* More intensive LDL-cholesterol lowering with the PCSK9 inhibitor evolocumab reduced major CV events in high-risk patients with prior PCI.
3. EuroPCR 2026 – Self-Expanding TAVR Valves Show Better Hemodynamics
* In patients with small aortic annuli, self-expanding valves provided better valve performance at 3 years, although clinical outcomes remained similar.
4. HRS 2026 – Rare Fatal Arrhythmias Reported After PFA
* Rare fatal ventricular arrhythmias were identified following pulsed-field ablation (PFA), highlighting the need for further safety evaluation.
5. EuroPCR 2026 – PCI vs CABG for Left Main Disease: 10-Year Outcomes
* Long-term survival was similar after PCI or coronary bypass surgery for left main coronary artery disease.
6. SCAI 2026 – Higher Lp(a) Levels Linked to Greater Risk
* Cardiovascular risk increased above 125 nmol/L, with the strongest association with death and stroke observed at Lp(a) levels ≥175 nmol/L.
7. EuroPCR 2026 – New Technologies Improve Treatment of Heavily Calcified Coronary Arteries
* Techniques such as shockwave therapy (IVL) and atherectomy are helping physicians better prepare heavily calcified arteries before stent implantation, improving procedural success.
8. EuroPCR 2026 – Novel Adaptive Coronary Implant Shows Excellent 4-Year Outcomes
* Unlike conventional metallic stents, this device is designed to allow the artery to adapt and move more naturally over time, with excellent 4-year outcomes..
9. FDA Approves Baxdrostat for Uncontrolled Hypertension
* Baxdrostat became the first approved aldosterone synthase inhibitor for patients with inadequately controlled hypertension.
10. SCAI 2026 – Clopidogrel Monotherapy Gains Support After DAPT
* A large study added support for clopidogrel monotherapy following DAPT cessation, reinforcing a growing trend in clinical practice.
Key Message:
EuroPCR 2026 dominated cardiovascular news in May 2026, with additional major updates emerging from HRS 2026, SCAI 2026, and the FDA approval of baxdrostat for hypertension.
http://www.tctmd.com/news/